XIUWANG WEI¹, JIANBO LIANG¹, HUANWEN HUANG¹, DAMING YANG¹, XINXIN WANG¹, XIUJIA WANG¹, CHANGSHENG CHEN¹, KAIQIANG LI¹, TAISEN PANG¹, BIN HU¹, FENGNING WU^2,*

Oncology Research, Vol.33, No.1, pp. 161-169, 2025, DOI:10.32604/or.2024.048054 - 20 December 2024

Abstract Background: Transmembrane emp24 trafficking protein 3 (TMED3) is associated with the development of several tumors; however, whether TMED3 regulates the progression of prostate cancer remains unclear. Materials and Methods: Short hairpin RNA was performed to repress TMED3 in prostate cancer cells (DU145 cells) and in a prostate cancer mice model to determine its function in prostate cancer in vitro and in vivo. Results: In the present study, we found that TMED3 was highly expressed in prostate cancer cells. In vitro, shTMED3 treatment suppressed the proliferation, invasion, and migration and promoted the apoptosis of DU145 cells. Additionally, the Kyoto Encyclopedia… More >

Noam Bar-Yaakov^1,2, Ziv Savin^1,2, Ibrahim Fahoum^2,3, Sophie Barnes^2,4, Yuval Bar-Yosef^1,2, Ofer Yossepowitch^1,2, Gal Keren-Paz^1,2, Roy Mano^1,2

Canadian Journal of Urology, Vol.31, No.1, pp. 11793-11801, 2024

Abstract Introduction: Prostate cancer screening with PSA is associated with low specificity; furthermore, little is known about the optimal timing of biopsy. We aimed to evaluate whether a risk classification system combining PSA density (PSAD) and mpMRI can predict clinically significant cancer and determine biopsy timing.
Materials and methods: We reviewed the medical records of 256 men with a PI-RADS ≥ 3 lesion on mpMRI who underwent transperineal targeted and systematic biopsies of the prostate between 2017-2019. Patients were stratified into three risk groups based on PSAD and mpMRI findings.
The study endpoint was clinically significant prostate cancer (CSPC).… More >

Ioana Fugaru¹, David Bouhadana¹, Gautier Marcq^2,3, Joseph Moryousef⁴, Alexis Rompré-Brodeur¹, Andrew Meng⁴, Oleg Loutochin¹, George Loutochin¹, Maurice Anidjar¹, Frank Bladou⁵, Rafael Sanchez-Salas¹

Canadian Journal of Urology, Vol.31, No.1, pp. 11784-11793, 2024

Abstract Introduction: Partial gland ablation (PGA) using high intensity focal ultrasound (HIFU) is an alternative to active surveillance for low to intermediate risk localized prostate cancer. This pilot study assessed quality of life (QoL) outcomes during the implementation of PGA HIFU at our institution.
Materials and methods: We prospectively enrolled 25 men with a diagnosis of localized low/intermediate risk prostate cancer who elected to undergo PGA-HIFU in a pilot study at our institution between 2013 and 2016. Patients underwent pre-treatment mpMRI and transrectal ultrasound-guided biopsies. The primary endpoints were impact on patient-reported functional outcomes (erectile, urinary function, QoL)… More >

Alex J. Xu¹, Sameer Thakker², Vyom Sawhney², Rozalba Gogaj¹, Fjolla Vokshi¹, James S. Wysock¹

Canadian Journal of Urology, Vol.31, No.1, pp. 11767-11774, 2024

Abstract Introduction: We evaluate the rate of developing ciprofloxacin resistance in patients undergoing repeat prostate biopsies (PBx), associated risk factors, and impact on complications.
Materials and methods: We retrospectively evaluated pre-procedural rectal culture (RCx) data in men undergoing PBx from 1/1/2016 to 1/15/2021. Univariate and multivariate logistic regression were utilized to identify risk factors associated with development of antibiotic resistance. Complication rates were compared between ciprofloxacin-sensitive and ciprofloxacin resistant patients.
Results: A total of 743 men underwent initial RCx. Initial RCx detected ciprofloxacin resistance in 22% of patients. A history of diabetes (p = 0.01), > 2 prior prostate… More >

Michelle K. Li, Orlando Diaz, Jonathan E. Katz

Canadian Journal of Urology, Vol.31, No.2, pp. 11861-11863, 2024

Abstract Standard treatment approaches for localized prostate cancer remain limited to active surveillance, radiotherapy, and radical prostatectomy. We present a case of transition zone prostate cancer that was treated with holmium laser enucleation of the prostate, a procedure that is normally reserved for the management of benign prostatic hyperplasia. More >

E. David Crawford¹, David Albala², Marc B. Garnick³, Andrew W. Hahn⁴, Paul Maroni⁵, Rana R. McKay⁶, Martin Miner⁷, Peter Orio III⁸, Kshitij Pandit¹, Scott Sellinger⁹, Evan Y. Yu¹⁰, Robert H. Eckel¹¹

Canadian Journal of Urology, Vol.31, No.2, pp. 11820-11825, 2024

Abstract Introduction: Risk of cardiovascular disease is higher among men with prostate cancer than men without, and prostate cancer treatments (especially those that are hormonally based) are associated with increased cardiovascular risk.
Materials and methods: An 11-member panel of urologic, medical, and radiation oncologists (along with a men’s health specialist and an endocrinologist/ preventive cardiologist) met to discuss current practices and challenges in the management of cardiovascular risk in prostate cancer patients who are taking androgen deprivation therapies (ADT) including LHRH analogues, alone and in combination with androgen-targeted therapies (ATTs).
Results: The panel developed an assessment algorithm to categorize… More >

Leonard G. Gomella

Canadian Journal of Urology, Vol.31, No.2, pp. 11814-11815, 2024

Abstract This article has no abstract. More >

Stephen E. Strup

Canadian Journal of Urology, Vol.31, No.3, pp. 11897-11897, 2024

Abstract This article has no abstract. More >

Shridhar C. Ghagane^1,3, Shadab Rangrez³, R.B. Nerli^2,3, Madhukar L. Thakur^4,6, Leonard G. Gomella^5,6

Canadian Journal of Urology, Vol.31, No.3, pp. 11892-11896, 2024

Abstract Introduction: Prostate cancer is the second most common malignancy in men worldwide. Genomic VPAC receptors are expressed on malignant prostate cancer cells and can be targeted and imaged optically by a peptide labeled fluorophore. The objective of our study was to assess the feasibility of detecting cancer of the prostate using a voided urine sample.
Materials and methods: Patients ≥ 40 years old, with lower urinary tract symptoms and serum PSA > 4 ng/ mL formed the study group. The first 50 mL of voided urine sample was collected and processed. The cells that were shed in… More >

Nikola C. Teslovich¹, Peter Elliott², Christopher S. Elliott²

Canadian Journal of Urology, Vol.31, No.3, pp. 11886-11891, 2024

Abstract Introduction: To define the smallest prostate needle biopsy (PNB) template necessary for accurate tissue diagnosis in men with markedly elevated PSA while decreasing procedural morbidity.
Materials and methods: We performed a chart review of 80 men presenting with a newly elevated PSA > 100 ng/mL who underwent biopsy (PNB or metastatic site). For patients who underwent a full 12-core biopsy, simulated templates of 2- to 10-cores were generated by randomly drawing subsets of biopsies from their full-template findings. Templates were iterated to randomize core location and generate theoretical smaller template outcomes. Simulated biopsy results were compared to… More >